Skip to main content

Genomics One Reports Lower Revenues, Higher Net Loss for 2004

NEW YORK, Feb. 21 (GenomeWeb News) - Genomics One reported last week an increased net loss in 2004 amid declining revenues.

According to the Quebec-based genomics products research firm, its sales for the year were down 11.7 percent to $328,426 from 2003. Genomics One attributed the drop to the weakening US dollar, which allowed American competitors to sell their products in Canada at reduced prices. As a result, Genomics One said it had to reduce the prices on its products to remain competitive.

Costs associated with commercialization and market development rose to $635,211 in 2004 from $535,349 the year before. Meanwhile, general and administrative expenses in 2004 dropped to $878,636 from about $1 million in 2003.

Genomics One posted a net loss of $798,932 in 2004, up from a loss of $589,972 in 2003.

The company had working capital of $871,463 at the end of 2004, and said that it seeking additional financing to ensure that it has resources to fund operations beyond 2005.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.